Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Intraindividual Comparison of Recognition of Symptom Burden in MPN between Patient- and Physician-Reported Assessment and Its Impact on Survival - an Analysis By the German Study Group for MPN (GSG-MPN)

Blood (2024) 144 (Supplement 1): 406.

https://doi.org/10.1182/blood-2024-206143

Published: 2024

Journal Articles

Real-World Outcomes with Ibrutinib in Patients with Chronic Lymphocytic Leukemia: Impact of Patient Typology on Adherence and Retention Rates within the German REALITY Study

Manfred Welslau, Sjaak Bloem, Rudolf Schlag, Steffen Dörfel, Sabrina Buchholz, Lukas Vornholz, Holger Schulz, Anke Gerhardt

Blood (2022) 140 (Supplement 1): 12400–12402.

https://doi.org/10.1182/blood-2022-156504

Published: 2022

Journal Articles

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

Mathias J Rummel, MD PhD, Christian Lerchenmüller, MD, Manfred Hensel, MD, Martin Goerner, MD, Christian Buske, MD PhD, Holger Schulz, Burkhard Schmidt, MD, Georgi Kojouharoff, MD, Elisabeth Lange, MD, Wolfgang Willenbacher, MD PhD, Jan Dürig, Erik Engel, Frank Kauff, Jürgen Barth, Alexander Christoph Burchardt, MD, Axel Hinke, PhD, Jasmin Wupperfeld, Richard Greil, MD

Blood (2019) 134 (Supplement_1): 343.

https://doi.org/10.1182/blood-2019-121909

Published: 2019

Journal Articles

Comorbidities Such As Thromboembolic Events Significantly Worsen Patient-Reported Quality of Life (QoL) and Symptoms in Myeloproliferative Neoplasms (MPN) - Data from the Bioregistry of the German Study Group for MPN (GSG-MPN)

Blood (2018) 132 (Supplement 1): 4292.

https://doi.org/10.1182/blood-2018-99-112377

Published: 2018

Journal Articles

Interim Results of the Observational Study Caro: Twice Weekly Carfilzomib Is a Convenient Treatment Option for Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy

Wolfgang Knauf, Andreas Ammon, Jens Uhlig, Marie Merling, Hans-Juergen Hurtz, Corinne Vannier, Holger Schulz, Norbert Marschner, Tamara Riedt, PhD, Karin Potthoff

Blood (2018) 132 (Supplement 1): 5662.

https://doi.org/10.1182/blood-2018-99-117996

Published: 2018

Journal Articles

Long-Term Disease Control in Patients with Primary Central Nervous System Lymphoma

Blood (2008) 112 (11): 3600.

https://doi.org/10.1182/blood.V112.11.3600.3600

Published: 2008

Journal Articles

Relapse of Central Nervous System Lymphoma after systemic Lymphoma (SCNSL): Clinical Features and Outcome as compared to Primary CNS Lymphoma (PCNSL) Patients

Blood (2008) 112 (11): 3602.

https://doi.org/10.1182/blood.V112.11.3602.3602

Published: 2008

Journal Articles

Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)

Holger Schulz, Ute Rehwald, Franck Morschhauser, Thomas Elter, Christoph Driessen, Thomas Rüdiger, Peter Borchmann, Roland Schnell, Volker Diehl, Andreas Engert, Marcel Reiser

Blood (2008) 111 (1): 109–111.

https://doi.org/10.1182/blood-2007-03-078725

Published: 2008

Includes: Supplemental data

Journal Articles

Chemotherapy Alone Versus Chemotherapy Plus Radiotherapy for Early Stage Hodgkin Lymphoma.

Fareed A. Rehan, Corinne Brillant, Holger Schulz, Ina Knauel, Julia Bohlius, Lena Specht, Andreas Engert

Blood (2007) 110 (11): 2320.

https://doi.org/10.1182/blood.V110.11.2320.2320

Published: 2007

Journal Articles

Early Relapses in Primary CNS Lymphoma (PCNSL) without Intraventricular Treatment.

Ingo G.H. Schmidt-Wolf, MD, Hendrick Pels, MD, Annika Jurgens, MD, Axel Glasmacher, MD, Holger Schulz, MD, Andreas Engert, MD, Michael Linnebank, MD, Gabriele Schackert, MD, Heinz Reichmann, MD, Frank Kroschinsky, MD, Marlies Vogt-Schaden, MD, Gertlinde Egerer, MD, Carlo Schaller, MD, Monika Lamprecht, MD, Ulrich Bogdahn, MD, Martina Deckert, MD, Rolf Fimmers, MD, Christoph Bangard, MD, Uwe Schlegel, MD

Blood (2007) 110 (11): 4440.

https://doi.org/10.1182/blood.V110.11.4440.4440

Published: 2007

Journal Articles

Combined Immunochemotherapy with Rituximab Improves Overall Survival in Patients with Follicular and Mantle Cell Lymphoma: Updated Meta-Analysis Results.

Holger Schulz, Julia Bohlius, Nicole Skoetz, Sven Trelle, Marcel Reiser, Thilo Kober, Guido Schwarzer, Michael Herold, Martin Dreyling, Andreas Engert

Blood (2006) 108 (11): 2760.

https://doi.org/10.1182/blood.V108.11.2760.2760

Published: 2006

Journal Articles

Necessity of Intraventricular Chemotherapy with the Modified Bonn Protocol in Primary CNS Lymphoma (PCNSL) Patients.

Ingo G.H. Schmidt-Wolf, MD, Hendrik Pels, MD, Annika Juergens, MD, Axel Glasmacher, MD, Holger Schulz, MD, Frank Kroschinsky, MD, Gertlinde Egerer, MD, Monika Lamprecht, MD, Caecilia Wismeth, MD, Uwe Schlegel, MD

Blood (2006) 108 (11): 2452.

https://doi.org/10.1182/blood.V108.11.2452.2452

Published: 2006

Journal Articles

Phase II Trial of the Bonn Polychemotherapy Protocol with Deferred Radiotherapy in Patients with Primary Central Nervous System Lymphoma.

Ingo G.H. Schmidt-Wolf, MD, Annika Juergens, MD, Hendrik Pels, MD, Axel Glasmacher, MD, Holger Schulz, MD, Andreas Engert, MD, Michael Linnebank, MD, Heinz Reichmann, MD, Frank Kroschinsky, MD, Marlies Vogt-Schaden, MD, Gerlinde Egerer, MD, Klaus Fliessbach, MD, Uwe Schlegel, MD

Blood (2006) 108 (11): 2453.

https://doi.org/10.1182/blood.V108.11.2453.2453

Published: 2006

Journal Articles

CHOP Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL with Autoimmune Hemolytic Anemia (AIHA) or Richter’s Transformation (RT): First Interim Analysis of a Phase II Trial of the German CLL Study Group (GCLLSG).

Barbara F. Eichhorst, MD, Raymonde Busch, Ulrich Duehrsen, MD, Holger Schulz, MD, Clemens M. Wendtner, MD, Maria E. Goebeler, MD, Michael Hallek, MD, and GCLLSG

Blood (2005) 106 (11): 2126.

https://doi.org/10.1182/blood.V106.11.2126.2126

Published: 2005

Journal Articles

Does Combined Immunochemotherapy with the Monoclonal Antibody Rituximab Improve Overall Survival in the Treatment of Patients with Indolent Non-Hodgkin Lymphoma? Preliminary Results of a Comprehensive Meta-Analysis.

Holger Schulz, MD, Nicole Skoetz, Julia Bohlius, MD, Sven Trelle, MD, Thilo Kober, Alexander Greb, Andreas Engert

Blood (2005) 106 (11): 351.

https://doi.org/10.1182/blood.V106.11.351.351

Published: 2005

Journal Articles

Rituximab in Relapsed Lymphocyte Predominant Hodgkin’s Disease (LPHD). Long-Term Results of a Phase-II Study from the German Hodgkin Lymphoma Study Group (GHSG).

Holger Schulz, MD, Sven Trelle, MD, Marcel Reiser, PhD, Marcus Sieber, MD, Volker Diehl, Andreas Engert

Blood (2005) 106 (11): 1503.

https://doi.org/10.1182/blood.V106.11.1503.1503

Published: 2005

Journal Articles

Polychemotherapy in patients with primary CNS lymphoma.

Axel Glasmacher, MD, Hendrik Pels, MD, Christoph Helmstaedter, MD, Martina Deckert, MD, Frank Kroschinsky, MD, Gabriele Schackert, MD, Heinz Reichmann, MD, Gerlinde Egerer, MD, Anthony Ho, MD, Holger Schulz, MD, Andreas Engert, MD, Volker Diehl, MD, Udo Bode, MD, Thomas Klockgether, MD, Uwe Schlegel, MD, Ingo G.H. Schmidt-Wolf, MD

Blood (2004) 104 (11): 3304.

https://doi.org/10.1182/blood.V104.11.3304.3304

Published: 2004

Journal Articles

Treatment of relapsed CD20 + Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group

Ute Rehwald, Holger Schulz, Marcel Reiser, Markus Sieber, Jan Oliver Staak, Franck Morschhauser, Christoph Driessen, Thomas Rüdiger, Konrad Müller-Hermelink, Volker Diehl, Andreas Engert

Blood (2003) 101 (2): 420–424.

https://doi.org/10.1182/blood.V101.2.420

Published: 2003

Journal Articles

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia

Holger Schulz, Saskia Karina Klein, Ute Rehwald, Marcel Reiser, Axel Hinke, Wolfgang-Ulrich Knauf, Walter-Erich Aulitzky, Manfred Hensel, Michael Herold, Dieter Huhn, Michael Hallek, Volker Diehl, Andreas Engert

Blood (2002) 100 (9): 3115–3120.

https://doi.org/10.1182/blood-2002-03-0972

Published: 2002

NARROW

Intraindividual Comparison of Recognition of Symptom Burden in MPN between Patient- and Physician-Reported Assessment and Its Impact on Survival - an Analysis By the German Study Group for MPN (GSG-MPN)

Real-World Outcomes with Ibrutinib in Patients with Chronic Lymphocytic Leukemia: Impact of Patient Typology on Adherence and Retention Rates within the German REALITY Study

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

Comorbidities Such As Thromboembolic Events Significantly Worsen Patient-Reported Quality of Life (QoL) and Symptoms in Myeloproliferative Neoplasms (MPN) - Data from the Bioregistry of the German Study Group for MPN (GSG-MPN)

Interim Results of the Observational Study Caro: Twice Weekly Carfilzomib Is a Convenient Treatment Option for Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy

Long-Term Disease Control in Patients with Primary Central Nervous System Lymphoma

Relapse of Central Nervous System Lymphoma after systemic Lymphoma (SCNSL): Clinical Features and Outcome as compared to Primary CNS Lymphoma (PCNSL) Patients

Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)

Chemotherapy Alone Versus Chemotherapy Plus Radiotherapy for Early Stage Hodgkin Lymphoma.

Early Relapses in Primary CNS Lymphoma (PCNSL) without Intraventricular Treatment.

Combined Immunochemotherapy with Rituximab Improves Overall Survival in Patients with Follicular and Mantle Cell Lymphoma: Updated Meta-Analysis Results.

Necessity of Intraventricular Chemotherapy with the Modified Bonn Protocol in Primary CNS Lymphoma (PCNSL) Patients.

Phase II Trial of the Bonn Polychemotherapy Protocol with Deferred Radiotherapy in Patients with Primary Central Nervous System Lymphoma.

CHOP Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL with Autoimmune Hemolytic Anemia (AIHA) or Richter’s Transformation (RT): First Interim Analysis of a Phase II Trial of the German CLL Study Group (GCLLSG).

Does Combined Immunochemotherapy with the Monoclonal Antibody Rituximab Improve Overall Survival in the Treatment of Patients with Indolent Non-Hodgkin Lymphoma? Preliminary Results of a Comprehensive Meta-Analysis.

Rituximab in Relapsed Lymphocyte Predominant Hodgkin’s Disease (LPHD). Long-Term Results of a Phase-II Study from the German Hodgkin Lymphoma Study Group (GHSG).

Polychemotherapy in patients with primary CNS lymphoma.

Treatment of relapsed CD20 + Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only